J&J Says Blackstone Will Bankroll Retinal Drug in $750M Funding Deal
Dow Jones11-16 21:56
Blackstone Life Sciences is committing $750 million to fully fund Phase three development of OLN324, the retinal drug J&J is acquiring through its Ollin Biosciences purchase. In exchange, Blackstone will receive regulatory and sales milestone payments plus single-digit royalties. The arrangement shifts development risk away from J&J while giving Blackstone exposure to a late-stage ophthalmology asset. The deal closes contingent on J&J completing the Ollin acquisition, which is expected before year-end, subject to regulatory approvals
This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments